Loading
Life sciences · Journal article
Nutrients · September 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Obesity-related metabolic dysfunction includes adipose inflammation, hepatic steatosis, insulin resistance, dyslipidemia, and intestinal disturbances. Avenanthramides are oat-specific phenolic amides, and their contribution to metabolic responses to oat foods is difficult to attribute because beta-glucan and the wider oat matrix can affect the same endpoints. This narrative review examines their mechanisms, exposure biology, evidence attribution, and translational readiness. Methods: Cell, animal, pharmacokinetic, and human studies were organized by chemical definition and intervention format, including purified congeners, characterized foods, enriched matrices, and whole-oat products. Parent compounds, circulating metabolites, target tissues, and clinical outcomes were interpreted separately. Results: In cell and animal models, avenanthramides influence NF-κB-related inflammation, redox regulation, hepatic insulin signaling, glucose production, fatty-acid metabolism, and intestinal ecology. Human studies demonstrate dietary exposure to parent compounds and metabolites, while clinical evidence comes mainly from small enriched-food exercise studies. Among the studies identified and appraised in this narrative review, none established an avenanthramide-specific effect on adiposity, liver fat, insulin sensitivity, dyslipidemia, or other cardiometabolic outcomes. Conclusions: The current literature supports measurable exposure and candidate mechanisms; a validated anti-obesity effect requires targeted clinical trials. Next studies need stable, analytically defined preparations, metabolite-informed dose selection, matched food controls, and trials that link measured exposure with prespecified clinical outcomes.